Important Legal Update for Regeneron Investors: Class Action
Regeneron Pharmaceuticals, Inc. and the Class Action Lawsuit
Investors and shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) should take note of significant developments as the Gross Law Firm announces a class action lawsuit. This legal action concerns accusations of misleading statements made by the company which could affect the interests of its shareholders.
Understanding the Class Period and Allegations
The class action pertains to shares purchased from a specified class period. Allegations against Regeneron claim that the company issued materially false and misleading statements, or failed to disclose crucial information regarding their pricing practices, specifically with their product, Eylea.
Details of the Allegations
During the class period, it is alleged that Regeneron paid credit card fees to distributors under the condition that they would not charge customers extra for purchasing Eylea with credit cards. This practice led to artificial inflation of Eylea sales figures, as these price concessions were not transparently reported. Furthermore, these actions may have violated regulations set forth in the False Claims Act.
Important Dates for Shareholders
Shareholders need to be aware of key dates related to the lawsuit. The deadline for investors to register for participation in this class action is set for March 10, 2025. Timely registration is crucial for those who wish to be recognized as lead plaintiffs or participate in any recovery that may result.
Next Steps for Shareholders
Upon registering, shareholders will receive benefits such as monitoring of their investment status. They will be kept informed about the case development and any necessary actions required from them.
The Role of Gross Law Firm
The Gross Law Firm stands out as a respected name in class action litigations, committed to safeguarding the rights of investors. Their focus is on addressing corporate misconduct and ensuring responsible business practices from companies like Regeneron. They aim to assist investors who have suffered due to deceptive practices, striving for justice and accountability.
Contact Information
For those seeking further information regarding this class action lawsuit or any related inquiries, please contact the Gross Law Firm. Their office is located at 15 West 38th Street, 12th floor, New York, NY 10018. Interested parties can reach out via phone or email for assistance with the claims process.
Frequently Asked Questions
What is the class period for this lawsuit?
The class period for this lawsuit runs from November 2, 2023, to October 30, 2024.
How can I register for the class action?
Interested shareholders can register their information through the Gross Law Firm’s class action portal before the deadline.
What are the allegations against Regeneron?
The allegations include misleading financial disclosures and failure to report significant pricing practices related to their Eylea product.
What should I do if I purchased shares of REGN?
If you purchased shares during the class period, it is advisable to register promptly to ensure your interests are protected.
Who can I contact for more information?
You can contact the Gross Law Firm for more details regarding the lawsuit or your participation.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
